81 related articles for article (PubMed ID: 23317234)
1. Expression of hPOT1 in HeLa cells and the probability of gene variation of hpot1 Exon14 in endometrial cancer are much higher than in other cancers.
Liu F; Pu XY; Huang SG; Xiang GM; Jiang DN; Hou G; Huang DN
Asian Pac J Cancer Prev; 2012; 13(11):5659-63. PubMed ID: 23317234
[TBL] [Abstract][Full Text] [Related]
2. Loss of hPot1 function leads to telomere instability and a cut-like phenotype.
Veldman T; Etheridge KT; Counter CM
Curr Biol; 2004 Dec; 14(24):2264-70. PubMed ID: 15620654
[TBL] [Abstract][Full Text] [Related]
3. Telomere 1 (POT1) gene expression and its association with telomerase activity in colorectal tumor samples with different pathological features.
Izgi A; Gunal A; Yalcin S; Gunduz U
Biomed Pharmacother; 2014 Sep; 68(7):841-6. PubMed ID: 25194444
[TBL] [Abstract][Full Text] [Related]
4. Silencing of the hPOT1 gene by RNA inference promotes apoptosis and inhibits proliferation and aggressive phenotype of gastric cancer cells, likely through up-regulating PinX1 expression.
Wan SM; Tie J; Zhang YF; Guo J; Yang LQ; Wang J; Xia SH; Yang SM; Wang RQ; Fang DC
J Clin Pathol; 2011 Dec; 64(12):1051-7. PubMed ID: 21778296
[TBL] [Abstract][Full Text] [Related]
5. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
6. [Human pot1 gene exon12 mutation screening in cultured human carcinoma cell strains (lines)].
Hou G; Huang DN; Jiang YH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jul; 26(7):991-3. PubMed ID: 16864095
[TBL] [Abstract][Full Text] [Related]
7. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado.
Enomoto T; Fujita M; Inoue M; Nomura T; Shroyer KR
Am J Clin Pathol; 1995 Feb; 103(2):224-30. PubMed ID: 7856567
[TBL] [Abstract][Full Text] [Related]
8. Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics.
Possemato R; Timmons JC; Bauerlein EL; Wada N; Baldwin A; Masutomi K; Hahn WC
Mol Cancer Res; 2008 Oct; 6(10):1582-93. PubMed ID: 18922974
[TBL] [Abstract][Full Text] [Related]
9. ras gene mutations in human endometrial carcinoma.
Varras MN; Koffa M; Koumantakis E; Ergazaki M; Protopapa E; Michalas S; Spandidos DA
Oncology; 1996; 53(6):505-10. PubMed ID: 8960147
[TBL] [Abstract][Full Text] [Related]
10. Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesis.
Gu P; Wang Y; Bisht KK; Wu L; Kukova L; Smith EM; Xiao Y; Bailey SM; Lei M; Nandakumar J; Chang S
Oncogene; 2017 Apr; 36(14):1939-1951. PubMed ID: 27869160
[TBL] [Abstract][Full Text] [Related]
11. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
12. [Application of mRNA differential display technique in screening related gene of endometrial carcinoma].
Meng Y; Wei L; Li C
Zhonghua Fu Chan Ke Za Zhi; 2001 Jun; 36(6):364-7. PubMed ID: 11783137
[TBL] [Abstract][Full Text] [Related]
13. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
14. Identification and partial characterization of differentially expressed mRNAs in normal human endometria and endometrial carcinomas by differential display RT-PCR.
Foca C; Rice GE; Quinn MA; Moses EK
Mol Hum Reprod; 2000 Aug; 6(8):712-8. PubMed ID: 10908281
[TBL] [Abstract][Full Text] [Related]
15. A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers.
Okada T; Akada M; Fujita T; Iwata T; Goto Y; Kido K; Okada T; Matsuzaki Y; Kobayashi K; Matsuno S; Sunamura M; Kawakami Y
Clin Cancer Res; 2006 Jan; 12(1):191-7. PubMed ID: 16397042
[TBL] [Abstract][Full Text] [Related]
16. Small non-coding RNA deregulation in endometrial carcinogenesis.
Ravo M; Cordella A; Rinaldi A; Bruno G; Alexandrova E; Saggese P; Nassa G; Giurato G; Tarallo R; Marchese G; Rizzo F; Stellato C; Biancardi R; Troisi J; Di Spiezio Sardo A; Zullo F; Weisz A; Guida M
Oncotarget; 2015 Mar; 6(7):4677-91. PubMed ID: 25686835
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Gründker C; Völker P; Emons G
Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
[TBL] [Abstract][Full Text] [Related]
18. Reverse transcription-polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers.
Lin Z; Nan Y; Zhang X; Zhao Y; Kim C; Kim I
Int J Gynecol Cancer; 2006; 16(4):1643-7. PubMed ID: 16884378
[TBL] [Abstract][Full Text] [Related]
19. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis.
Naito M; Satake M; Sakai E; Hirano Y; Tsuchida N; Kanzaki H; Ito Y; Mori T
Jpn J Cancer Res; 1992 Oct; 83(10):1030-6. PubMed ID: 1333465
[TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
